Advertisement
Advertisement
PTGX
Protagonist Therapeutics, Inc
144.83
USDSponsored
+2.69
+1.89%
Oct 29, 13:06 UTC -4
Open
Protagonist Therapeutics, Inc (PTGX) Earnings
PTGX Earnings Reports
Positive Surprise Ratio
PTGX beat 25 of 41 last estimates.
61%
Next Report
Next Week
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$243.24M
/$2.49
Implied change from Q2 26 (Revenue/ EPS)
+13.94%
/+8.73%
Implied change from Q3 25 (Revenue/ EPS)
+5062.04%
/-501.61%
Protagonist Therapeutics, Inc earnings per share and revenue
On Aug 05, 2026, PTGX reported earnings of 2.29 USD per share (EPS) for Q2 26, beating the estimate of 2.12 USD, resulting in a 7.83% surprise. Revenue reached 213.47 million, compared to an expected 207.84 million, with a 2.71% difference. The market reacted with a +1.11% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of 2.49 USD, with revenue projected to reach 243.24 million USD, implying an increase of 8.73% EPS, and increase of 13.94% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
MiMedx Group, Inc
Report Date
Oct 28, 2026 For Q3 26
Estimate
-$0.01
Actual
-$0.01
Surprise
+26.47%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.14
Actual
$0.04
Surprise
+128.27%
FAQ
What were Protagonist Therapeutics, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Protagonist Therapeutics, Inc reported EPS of $2.29, beating estimates by 7.83%, and revenue of $213.47M, 2.71% above expectations.
How did the market react to Protagonist Therapeutics, Inc's Q2 2026 earnings?
The stock price moved up 1.11%, changed from $135.81 before the earnings release to $137.32 the day after.
When is Protagonist Therapeutics, Inc expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Protagonist Therapeutics, Inc's next earnings report?
Based on 12
analysts, Protagonist Therapeutics, Inc is expected to report EPS of $2.49 and revenue of $243.24M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.